Author

Silvio Danese

Planning the patient’s journey to success in Crohn’s disease (Janssen)
Planning the patient’s journey to success in Crohn’s disease (Janssen)

Silvio Danese  et al.

HEALTH-RELATED QUALITY OF LIFE WITH USTEKINUMAB VERSUS ADALIMUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: IBDQ IN THE SEAVUE STUDY
HEALTH-RELATED QUALITY OF LIFE WITH USTEKINUMAB VERSUS ADALIMUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: IBDQ IN THE SEAVUE STUDY

Silvio Danese  et al.

IBD treatment algorithm driven by AI
IBD treatment algorithm driven by AI

Silvio Danese

ASSESSMENT OF COMPOSITE ENDPOINTS COMPRISING SYMPTOMATIC, HISTOLOGIC, ENDOSCOPIC, AND MOLECULAR IMPROVEMENT IN A PHASE 1B STUDY OF GB004, A GUT-TARGETED, HYPOXIA-INDUCIBLE FACTOR (HIF)-1? STABILIZER, IN MILD-TO-MODERATE ULCERATIVE COLITIS
ASSESSMENT OF COMPOSITE ENDPOINTS COMPRISING SYMPTOMATIC, HISTOLOGIC, ENDOSCOPIC, AND MOLECULAR IMPROVEMENT IN A PHASE 1B STUDY OF GB004, A GUT-TARGETED, HYPOXIA-INDUCIBLE FACTOR (HIF)-1? STABILIZER, IN MILD-TO-MODERATE ULCERATIVE COLITIS

SAFETY OF USTEKINUMAB ACROSS APPROVED ADULT INDICATIONS: POOLED SAFETY ANALYSIS IN CROHN’S DISEASE, ULCERATIVE COLITIS, PSORIASIS, AND PSORIATIC ARTHRITIS THROUGH UP TO 5 YEARS
SAFETY OF USTEKINUMAB ACROSS APPROVED ADULT INDICATIONS: POOLED SAFETY ANALYSIS IN CROHN’S DISEASE, ULCERATIVE COLITIS, PSORIASIS, AND PSORIATIC ARTHRITIS THROUGH UP TO 5 YEARS

Silvio Danese  et al.

RAPIDITY OF SYMPTOM IMPROVEMENTS DURING FILGOTINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY
RAPIDITY OF SYMPTOM IMPROVEMENTS DURING FILGOTINIB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY

Silvio Danese  et al.

SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION AS AN OPTION FOR MANAGING THE LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE: POST HOC ANALYSIS OF LIBERTY-UC STUDY AND LIBERTY-CD STUDY
SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION AS AN OPTION FOR MANAGING THE LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE: POST HOC ANALYSIS OF LIBERTY-UC STUDY AND LIBERTY-CD STUDY

Silvio Danese  et al.

Evolving treatment goals and unmet needs in ulcerative colitis: how to address the gaps? (Takeda Pharmaceuticals International AG)
Evolving treatment goals and unmet needs in ulcerative colitis: how to address the gaps? (Takeda Pharmaceuticals International AG)

Silvio Danese  et al.

CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY
CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY

SYMPTOMS AND LABORATORY VALUES AS PROXIES FOR ENDOSCOPIC AND HISTOLOGIC CLINICAL ENDPOINTS IN ULCERATIVE COLITIS: A MEDIATION ANALYSIS BASED ON UPADACITINIB PHASE 3 INDUCTION TRIALS
SYMPTOMS AND LABORATORY VALUES AS PROXIES FOR ENDOSCOPIC AND HISTOLOGIC CLINICAL ENDPOINTS IN ULCERATIVE COLITIS: A MEDIATION ANALYSIS BASED ON UPADACITINIB PHASE 3 INDUCTION TRIALS

How Might Oral Small Molecule Therapies Change Care in Ulcerative Colitis? (Bristol Myers Squibb)
How Might Oral Small Molecule Therapies Change Care in Ulcerative Colitis? (Bristol Myers Squibb)

Silvio Danese  et al.

Weighing up treatment options in UC: how do we interpret the evidence for JAK inhibition? (Pfizer)
Weighing up treatment options in UC: how do we interpret the evidence for JAK inhibition? (Pfizer)

Silvio Danese  et al.

Opening the door to emerging investigational treatments in ulcerative colitis: What awaits us? (Arena Pharmaceuticals)
Opening the door to emerging investigational treatments in ulcerative colitis: What awaits us? (Arena Pharmaceuticals)

Silvio Danese  et al.

Ulcerative colitis: Today, tomorrow and the future (Gilead & Galapagos)
Ulcerative colitis: Today, tomorrow and the future (Gilead & Galapagos)

Silvio Danese  et al.

DURABILITY OF SYMPTOMATIC AND CLINICAL OUTCOMES IN OZANIMOD-TREATED PATIENTS BY ENDPOINTS OF INCREASING OBJECTIVITY AT TRUE NORTH WEEK 52: INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
DURABILITY OF SYMPTOMATIC AND CLINICAL OUTCOMES IN OZANIMOD-TREATED PATIENTS BY ENDPOINTS OF INCREASING OBJECTIVITY AT TRUE NORTH WEEK 52: INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION STUDY

Silvio Danese  et al.

EFFECT OF ETRASIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
EFFECT OF ETRASIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Silvio Danese  et al.

PRA023, AN ANTI-TL1A INHIBITORY ANTIBODY, REDUCED INFLAMMATORY AND FIBROSIS ASSOCIATED BIOMARKERS IN ULCERATIVE COLITIS PATIENTS WHO ACHIEVED CLINICAL REMISSION
PRA023, AN ANTI-TL1A INHIBITORY ANTIBODY, REDUCED INFLAMMATORY AND FIBROSIS ASSOCIATED BIOMARKERS IN ULCERATIVE COLITIS PATIENTS WHO ACHIEVED CLINICAL REMISSION

Silvio Danese  et al.

WORLDWIDE POST-MARKETING SAFETY SURVEILLANCE EXPERIENCE WITH TOFACITINIB IN ULCERATIVE COLITIS
WORLDWIDE POST-MARKETING SAFETY SURVEILLANCE EXPERIENCE WITH TOFACITINIB IN ULCERATIVE COLITIS

Dynamic management of CD: reaching a new dimension in patient care (Janssen)
Dynamic management of CD: reaching a new dimension in patient care (Janssen)

Silvio Danese  et al.

EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-1 INDUCTION TRIAL
EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-1 INDUCTION TRIAL

Silvio Danese  et al.

Item 21 - 40 / 152
1
2
3 4 5 6 7 8